Current Biology
Volume 24, Issue 19, 6 October 2014, Pages 2274-2280
Journal home page for Current Biology

Report
The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation

https://doi.org/10.1016/j.cub.2014.08.007Get rights and content
Under an Elsevier user license
open archive

Highlights

  • The mTORC1 pathway positively regulates GLS and glutamine flux

  • mTORC1 controls the translation efficiency of Myc mRNA

  • S6K1 regulates Myc translation through eIF4B phosphorylation

  • Inhibition of GLS decreases the growth of pancreatic cancer cells

Summary

Growth-promoting signaling molecules, including the mammalian target of rapamycin complex 1 (mTORC1), drive the metabolic reprogramming of cancer cells required to support their biosynthetic needs for rapid growth and proliferation [1]. Glutamine is catabolyzed to α-ketoglutarate (αKG), a tricarboxylic acid (TCA) cycle intermediate, through two deamination reactions, the first requiring glutaminase (GLS) to generate glutamate and the second occurring via glutamate dehydrogenase (GDH) or transaminases [2]. Activation of the mTORC1 pathway has been shown previously to promote the anaplerotic entry of glutamine to the TCA cycle via GDH. Moreover, mTORC1 activation also stimulates the uptake of glutamine, but the mechanism is unknown [3]. It is generally thought that rates of glutamine utilization are limited by mitochondrial uptake via GLS, suggesting that, in addition to GDH, mTORC1 could regulate GLS. Here we demonstrate that mTORC1 positively regulates GLS and glutamine flux through this enzyme. We show that mTORC1 controls GLS levels through the S6K1-dependent regulation of c-Myc (Myc). Molecularly, S6K1 enhances Myc translation efficiency by modulating the phosphorylation of eukaryotic initiation factor eIF4B, which is critical to unwind its structured 5′ untranslated region (5′UTR). Finally, our data show that the pharmacological inhibition of GLS is a promising target in pancreatic cancers expressing low levels of PTEN.

Cited by (0)

6

Co-first author

7

Present address: Infinity Pharmaceuticals, 780 Memorial Drive, Cambridge, MA 02139, USA